BioCentury
ARTICLE | Finance

Breaking from tradition

Why Tony Coles' Yumanity assembled a non-traditional series A syndicate

February 15, 2016 8:00 AM UTC

Traditional VCs are missing from the new series A syndicate backing Yumanity Therapeutics LLC, and the biotech says that was its plan. The neurodegeneration company wanted investors with exceedingly long time horizons and the ability to support it in the private and public arenas.

Last week, Yumanity raised $45 million in a round led by Fidelity. Redmile Group, Alexandria Venture Investments, Biogen Inc. (NASDAQ:BIIB), Sanofi-Genzyme BioVentures and Dolby Family Ventures also participated...